• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Sohi on the future of PSMA-PET imaging in prostate cancer


In this video, Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer. Sohi is a nuclear medicine physician with Northwestern University and American Molecular Imaging.


PSMA-PET has only been around for about 3 years, give or take, and you can see it's already made a tremendous impact in utilization and impacting patient care. It has facilitated more accurate staging and restaging of these patients with prostate carcinoma. I think the utilization of this modality, this tracer, will only increase when we look down the road 5 to 10 years from now. I think it is feasible to see PSMA-PET being used at an even earlier time point, which would mean using this imaging modality in conjunction with MRI to evaluate patients with signs and symptoms that are concerning for potential prostate carcinoma (rising or abnormal PSA levels) to basically help diagnose the patient. And there might even be the potential that one day PSMA-PET imaging could actually replace MRI, but that is yet to be determined.

Transcription has been edited for clarity.

Related Videos
Dr. Daniel Spratt in an interview with Urology Times
© 2024 MJH Life Sciences

All rights reserved.